Neurofibromatosis: NF1 and NF2-Related Schwannomatosis

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • NF2 is now "NF2-related schwannomatosis"; the 2021–2022 criteria include genetic and mosaic forms .
  • NF1 OPG:
    • in 15–20%, almost always under age 7;
    • treat for vision loss with chemotherapy, not surgery .
    • About 44% need second-line treatment; age under 2 and posterior location predict failure .
  • Selumetinib: 70% partial response in inoperable plexiform neurofibroma and 40% in NF1 low-grade glioma .
  • MPNST: 8–13% lifetime risk, presenting decades earlier than sporadic MPNST, with 21% 5-year survival. Pain or rapid growth means work it up .
  • NF1 also brings moyamoya, dystrophic spine and dural ectasia .
  • NF2-related schwannomatosis: bilateral vestibular schwannomas. Bevacizumab shrinks most growing tumors and improves hearing in some (4 of 7) .

Landmark papers

  • SPRINT (Gross et al., N Engl J Med 2020): a phase 2 trial of selumetinib in 50 children with symptomatic inoperable plexiform neurofibromas. 70% had a confirmed partial response .
  • Selumetinib in low-grade glioma (Fangusaro et al., Lancet Oncol 2019): a multicentre phase 2 trial in recurrent NF1-associated low-grade glioma. A sustained partial response occurred in 10 of 25 (40%) .

The "neurofibromatoses" are genetically distinct tumor-predisposition syndromes:

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:neurofibromatosis:3b85eaa8b3c43d2f© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.NF1: child with cafe-au-lait macules, axillary freckling and cutaneous neurofibromas, Lisch nodules, optic pathway glioma, plexiform neurofibroma with an MPNST focus, dystrophic spine with scalloping and dural ectasia, and moyamoya. NF2-related schwannomatosis: bilateral vestibular schwannomas, meningiomas, spinal schwannomas and intramedullary ependymoma. RAS-MAPK with selumetinib and VEGF with bevacizumab(A) NF1axillaryfrecklingcafe-au-laitmacules (6+)cutaneousneurofibromasLischnodulesoptic pathway glioma: fusiform nerves, chiasmnervechiasmoptic tractsplexiform neurofibroma:"bag of worms" alonga nerve trunkMPNST: enlarging,painful, heterogeneous,necrotic (PET-avid)dystrophic spineposterior scallopingdural ectasiashort, sharp curve; wedged, rotatedvertebrae; pencilled ribsNF1 vasculopathy: moyamoyasupraclinoid ICAstenosis"puff of smoke"lenticulostriatecollateralsnormal side:MCA, ACA(B) NF2-RELATED SCHWANNOMATOSIS (T1 + CONTRAST)bilateral VS (IAC + CPA)meningiomafalxIMschw.NF2-related schwannomatosis:- bilateral vestibular schwannomas (hallmark; hearing loss, tinnitus)- meningiomas: convexity, falx, skull base, spinal- spinal schwannomas (extramedullary, dumbbell) on nerve roots- intramedullary ependymoma (cervical)- juvenile cataract, retinal hamartomaMRI: brain + whole spine; audiology(C) TARGETED THERAPYRTKRAS-GTPRAFMEKERKgrowthneurofibromin(NF1: RAS-GAP)selumetinibplexiform NF, LGGVEGFbevacizumabgrowing VS (NF2)
Neurofibromatoses. (a) NF1: café-au-lait macules, axillary freckling, cutaneous neurofibromas, Lisch nodules; optic pathway glioma along the optic nerves and chiasm; plexiform neurofibroma along a nerve trunk with a focus of malignant change (MPNST); dystrophic scoliosis; moyamoya. (b) NF2-related schwannomatosis: bilateral vestibular schwannomas at the internal auditory canals, meningiomas, spinal schwannomas and intramedullary ependymoma. (c) Drugs by target: MEK inhibitor (selumetinib) for NF1 plexiform neurofibroma and low-grade glioma; anti-VEGF (bevacizumab) for growing vestibular schwannomas. Not to scale.

NF1

Optic pathway glioma (OPG)

Plexiform neurofibromas and MPNST

Other NF1 issues for the neurosurgeon

NF2-related schwannomatosis

Related topics

References

  1. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 2022;24(9):1967–1977. doi:10.1016/j.gim.2022.05.007. PMID 35674741. verified
  2. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021;23(8):1506–1513. doi:10.1038/s41436-021-01170-5. PMID 34012067. verified
  3. Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61(3):189–198. doi:10.1002/ana.21107. PMID 17387725. verified
  4. Kotch C, Avery R, Getz KD, et al. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro Oncol 2022;24(8):1377–1386. doi:10.1093/neuonc/noac013. PMID 35018469. verified
  5. Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20(7):1011–1022. doi:10.1016/S1470-2045(19)30277-330277-3). PMID 31151904. verified
  6. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020;382(15):1430–1442. doi:10.1056/NEJMoa1912735. PMID 32187457. verified
  7. Kotch C, de Blank P, Fangusaro J, et al. MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors. Neurooncol Adv 2026;8(Suppl 2):ii14–ii24. doi:10.1093/noajnl/vdae223. PMID 42059002. verified
  8. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39(5):311–314. doi:10.1136/jmg.39.5.311. PMID 12011145. verified
  9. Lehman LL, Ullrich NJ. Cerebral vasculopathy in children with neurofibromatosis type 1. Cancers (Basel) 2023;15(20):5111. doi:10.3390/cancers15205111. PMID 37894478. verified
  10. Forde C, King AT, Rutherford SA, et al. Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol 2021;23(7):1113–1124. doi:10.1093/neuonc/noaa284. PMID 33336705. verified
  11. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361(4):358–367. doi:10.1056/NEJMoa0902579. PMID 19587327. verified

Verification (2026-11-17):

Caveats: